Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 23421906)

1.

"Omics" of HER2-positive breast cancer.

Bravatà V, Cammarata FP, Forte GI, Minafra L.

OMICS. 2013 Mar;17(3):119-29. doi: 10.1089/omi.2012.0099. Epub 2013 Feb 19. Review.

PMID:
23421906
2.

Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.

Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G.

J Pathol. 2005 Apr;205(5):577-84.

PMID:
15732132
3.

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

Breast Cancer Res. 2008;10(3):R46. doi: 10.1186/bcr2098. Epub 2008 May 16.

6.

Targeting HER2: recent developments and future directions for breast cancer patients.

Wang SC, Zhang L, Hortobagyi GN, Hung MC.

Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. Review.

PMID:
11774202
8.

[Molecular protocol for HER2/neu analysis in breast carcinoma].

Artufel MV, Valero AC, Lladó RR, Sagalés NE, Llorca MC, Carazo AM, Cardó CC, Torrus XP.

Clin Transl Oncol. 2005 Dec;7(11):504-11. Spanish.

PMID:
16373062
9.

Prognostic and predictive value of HER2/neu oncogene in breast cancer.

Masood S, Bui MM.

Microsc Res Tech. 2002 Oct 15;59(2):102-8. Review.

PMID:
12373720
10.

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.

Hanna W, Nofech-Mozes S, Kahn HJ.

Breast J. 2007 Mar-Apr;13(2):122-9.

PMID:
17319852
11.

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Roka S, Bachleitner T, Kandioler D, Steger G, Mittlböck M, Jakesz R.

Wien Klin Wochenschr. 2004 Jan 31;116(1-2):26-31.

PMID:
15030120
14.

Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.

Cuadros M, Talavera P, López FJ, García-Peréz I, Blanco A, Concha A.

Pathobiology. 2010;77(1):38-45. doi: 10.1159/000272953. Epub 2010 Feb 25.

PMID:
20185966
15.

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.

Chan A, McGregor SR.

Intern Med J. 2012 Mar;42(3):267-74. doi: 10.1111/j.1445-5994.2011.02432.x.

PMID:
21241440
16.

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM.

Eur J Cancer. 2004 Jan;40(1):56-63.

PMID:
14687790
17.

Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.

Umekita Y, Souda M, Ohi Y, Sagara Y, Rai Y, Takahama T, Yoshida H.

Pathol Int. 2006 Aug;56(8):423-7.

PMID:
16872435
18.

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.

Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.

Int J Oncol. 2007 Feb;30(2):509-20.

PMID:
17203234
19.

Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.

Li P, Liu T, Wang Y, Shao S, Zhang W, Lv Y, Yi J, Wang Z.

Clin Breast Cancer. 2013 Feb;13(1):53-60. doi: 10.1016/j.clbc.2012.09.011. Epub 2012 Oct 26.

PMID:
23103368
20.

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM.

Mol Cancer. 2008 Dec 15;7:91. doi: 10.1186/1476-4598-7-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk